Details of the Drug

General Information of Drug (ID: DM5TB76)

Drug Name
DACRA 089
Synonyms KBP-089
Indication
Disease Entry ICD 11 Status REF
Type 2 diabetes 5A11 Phase 1 [1]
Drug Type
Peptide
Cross-matching ID
TTD ID
DW3J9N

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Amylin receptor (IAPPR) TTAT87F CALCR_HUMAN-RAMP1_HUMAN/RAMP2_HUMAN/RAMP3_HUMAN Agonist [2]
Calcitonin receptor (CALCR) TTLWS2O CALCR_HUMAN Agonist [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Type 2 diabetes
ICD Disease Classification 5A11
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Calcitonin receptor (CALCR) DTT CALCR 7.52E-03 0.17 2.26
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03907202) A Clinical Study to Evaluate the Safety, Tolerability, PK, PD, and Efficacy of KBP-089 in Patients With T2DM. U.S. National Institutes of Health.
2 A novel dual amylin and calcitonin receptor agonist, KBP-089, induces weight loss through a reduction in fat, but not lean mass, while improving food preference. Br J Pharmacol. 2017 Apr;174(7):591-602.